Caprelsa (vandetanib) / Sanofi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
ZEAL, NCT00418886 / 2006-003695-35: Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Checkmark Data
Feb 2011 - Feb 2011: Data
Completed
3
698
Europe, US, RoW
Vandetanib, ZACTIMA™, ZD6474, SAR390530, Pemetrexed, Pemetrexed disodium, Alimta®
Genzyme, a Sanofi Company
Non Small Cell Lung Cancer, Lung Cancer
09/08
02/23
NCT00410761 / 2005-005077-29: An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Checkmark P2 data (MTC)
Jan 2012 - Jan 2012: P2 data (MTC)
Checkmark P3 data
Oct 2011 - Oct 2011: P3 data
Active, not recruiting
3
437
Europe, Canada, US, RoW
ZD6474 (Vandetanib), ZACTIMA™, SAR390530
Genzyme, a Sanofi Company
Thyroid Cancer
07/09
06/24
NCT01298323 / 2010-023428-26: Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Active, not recruiting
3
205
Europe, Canada, RoW
Patient outreach, Vandetanib, SAR390530
Genzyme, a Sanofi Company
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
04/13
06/24
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
AcceleRET-MTC, NCT04760288 / 2020-005269-15: A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn
3
198
Europe
Pralsetinib, Cabozantinib, Vandetanib
Hoffmann-La Roche
Medullary Thyroid Cancer
10/27
04/35
2020-001270-29: Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients

Ongoing
2/3
350
Europe, RoW
SAR390530, Tablet, PLAQUENIL 200 mg, comprimé pelliculé
sanofi-aventis recherche & développement, sanofi-aventis recherche & développement
Coronavirus infection, Coronavirus infection, Diseases [C] - Virus Diseases [C02]
 
 

Download Options